☆ 4.6 Editorial Material

How Does CREDENCE Inform Best Use of SGLT2 Inhibitors in CKD?

CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2019)

Get Full Text
Add to Collection

Journal

CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
Volume 14, Issue 11, Pages 1667-1669

Publisher

AMER SOC NEPHROLOGY
DOI: 10.2215/CJN.05340419

Keywords

chronic renal insufficiency; chronic kidney disease; Sodium-Glucose Transporter 2; Hypoglycemic Agents; end stage kidney disease; cardiovascular disease; cardiovascular outcomes; Canagliflozin; diabetes; type 2 diabetes

Categories

Urology & Nephrology

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.